RNA m 5 C modification upregulates E2F1 expression in a manner dependent on YBX1 phase separation and promotes tumor progression in ovarian cancer
Xiaoyi Liu,Qinglv Wei,Chenyue Yang,Hongyan Zhao,Jie Xu,Youchaou Mobet,Qingya Luo,Dan Yang,Xinzhao Zuo,Ningxuan Chen,Yu Yang,Li Li,Wei Wang,Jianhua Yu,Jing Xu,Tao Liu,Ping Yi
DOI: https://doi.org/10.1038/s12276-024-01184-4
2024-03-02
Experimental & Molecular Medicine
Abstract:5-Methylcytosine (m 5 C) is a common RNA modification that modulates gene expression at the posttranscriptional level, but the crosstalk between m 5 C RNA modification and biomolecule condensation, as well as transcription factor-mediated transcriptional regulation, in ovarian cancer, is poorly understood. In this study, we revealed that the RNA methyltransferase NSUN2 facilitates mRNA m 5 C modification and forms a positive feedback regulatory loop with the transcription factor E2F1 in ovarian cancer. Specifically, NSUN2 promotes m 5 C modification of E2F1 mRNA and increases its stability, and E2F1 binds to the NSUN2 promoter, subsequently reciprocally activating NSUN2 transcription. The RNA binding protein YBX1 functions as the m 5 C reader and is involved in NSUN2-mediated E2F1 regulation. m 5 C modification promotes YBX1 phase separation, which upregulates E2F1 expression. In ovarian cancer, NSUN2 and YBX1 are amplified and upregulated, and higher expression of NSUN2 and YBX1 predicts a worse prognosis for ovarian cancer patients. Moreover, E2F1 transcriptionally regulates the expression of the oncogenes MYBL2 and RAD54L, driving ovarian cancer progression. Thus, our study delineates a NSUN2-E2F1-NSUN2 loop regulated by m 5 C modification in a manner dependent on YBX1 phase separation, and this previously unidentified pathway could be a promising target for ovarian cancer treatment.
biochemistry & molecular biology,medicine, research & experimental